DIVINCELL is very proud to announce the successfully validation of Veronica Guzman Gonzalez's Thesis. This excellent work was carries out in collaboration with the team of Virginie Faure and Jean-Luc Coll at IAB Institute for Advanced Biosciences Université Grenoble Alpes, within the framework of Cifre grant supported by the ANRT - Association Nationale de la Recherche et de la Technologie. Congratulations Veronica for this tremendous work!!!! #KRAS #CRISPR #nanomedicine #nanotechnology #drugdelivery #mRNA #cancer
PhD in biotechnology | mRNA therapeutics | Cell & Gene therapy | Nanomedicine
🎓 Exciting milestone achieved: Ph.D. Thesis in cutting-edge nanomedicine successfully defended! After years of dedication, exploration, and stubborn perseverance, I am thrilled to announce the successful defense of my Ph.D. thesis at Université Grenoble Alpes. This journey has been both challenging and rewarding, and I owe immense gratitude to the remarkable individuals who supported me throughout. First and foremost, I want to express my heartfelt appreciation to my academic supervisor, Dr. Virginie Faure, whose guidance and mentorship have been invaluable on this academic journey. Additionally, I extend my deepest thanks to my industrial supervisor from DIVINCELL, Dr. Divita Gilles, for his unwavering support and insightful contributions that enriched my Ph.D. experience. I am also grateful to Dr. Jean-Luc Coll for believing in my potential and giving me the opportunity to join his research group. I must also acknowledge the esteemed members of the jury: Dr. Alice Carrier, Dr. Emmanuel GARCION, Prof. Jean-Luc Lenormand, and Dr. Nadire Bettache. Their rigorous evaluation, discussions, and constructive critiques during my defense have further strengthened my work and my commitment to advancing the field of nanomedicine. 💡 Imagine a future where we possess the ability to design a precision weapon against cancer, targeting malignant cells while sparing healthy ones. Nanoparticles have emerged as this 'magic bullet' capable of delivering drugs, DNA, RNA, and even revolutionary gene-editing technologies like CRISPR-Cas9. My Ph.D. thesis contributes a significant step toward this audacious goal, presenting a novel therapeutic approach utilizing peptide based nanoparticles for the targeted delivery of CRISPR-Cas9 to combat one of the most frequently mutated oncogenes in human cancer — the KRAS gene. Thank you to everyone who has been part of this journey. I look forward to continuing to push the boundaries of science and make a positive impact on the future of healthcare.
